Navigation Links
Lexicon Announces Pricing of Common Stock in Public Offering
Date:3/16/2010

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the public offering and concurrent private placement. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Words such as "anticipated," "will," "proposed," and similar expressions are intended to identify these forward-looking statements.  There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering and concurrent private placement.  There can be no assurance that Lexicon will be able to complete the public offering or concurrent private placement on the anticipated terms, or at all.  Additional risks and uncertainties relating to the public offering and concurrent private placement, Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission and under the heading "Risk Factors" in the final prospectus supplement related to the public offering to be filed with the Securities and Exchange Commission.  Unless required by applicable law, Lexicon undertakes no obligation to update or revise any such forward-looking s
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
2. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
3. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
5. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
6. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
7. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
8. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
9. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
10. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
11. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... After the boom of the energy ... beverage craze is going to be the stress relief ... use Stress Relief energy pattern which can be applied ... a beverage, including minerals, herbs and liquids. Stress Relief ... power into rapid recovery and helping to adapt more ...
(Date:8/27/2014)... August 27, 2014 WriteResult, LLC – ... has once again shown superiority when it comes to ... completing the ePRO portion of their most recent study ... Japan-based pharma chose WriteResult’s digital writing platform to collect ... the first to complete drew data from a number ...
(Date:8/26/2014)... , Aug. 26, 2014  NeuroSigma, Inc., a ... to develop bioelectronic technologies, today announced that it has ... U.S. Securities and Exchange Commission relating to a proposed ... of shares to be offered and the price range ... Jefferies LLC will act as the book-running ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Research Inc., (TSX:,ARI), a biotechnology company discovering and ... its financial and operational,results for the third quarter, ... of fiscal 2007 was one of preparation as ... into human clinical trials in,2008, while also building ...
... N.C., Oct. 12 Campbell Alliance, the leading,management ... today announced that Ben Bonifant, Vice President,of the ... at the Licensing Executive Society (LES) Annual Meeting. ... at the Vancouver Convention and,Exhibit Centre in Vancouver, ...
... 12 QuantiFERON(R)-TB Gold,In- Tube is Poised to ... for,Accurate & Effective Tuberculosis Screening October 12 ... controllers around the,country can now quickly and accurately ... Drug Administration (FDA) approval of,QuantiFERON(R)-TB Gold In-Tube (QFT(TM)). ...
Cached Biology Technology:ARIUS Announces Third Quarter Fiscal 2007 Financial Results 2ARIUS Announces Third Quarter Fiscal 2007 Financial Results 3ARIUS Announces Third Quarter Fiscal 2007 Financial Results 4ARIUS Announces Third Quarter Fiscal 2007 Financial Results 5ARIUS Announces Third Quarter Fiscal 2007 Financial Results 6ARIUS Announces Third Quarter Fiscal 2007 Financial Results 7ARIUS Announces Third Quarter Fiscal 2007 Financial Results 8ARIUS Announces Third Quarter Fiscal 2007 Financial Results 9ARIUS Announces Third Quarter Fiscal 2007 Financial Results 10ARIUS Announces Third Quarter Fiscal 2007 Financial Results 11ARIUS Announces Third Quarter Fiscal 2007 Financial Results 12ARIUS Announces Third Quarter Fiscal 2007 Financial Results 13ARIUS Announces Third Quarter Fiscal 2007 Financial Results 14ARIUS Announces Third Quarter Fiscal 2007 Financial Results 15Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 2Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver 3Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 3
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... hours ago the Happy Camp Complex of fires had ... July complex had consumed 35,530 as of eight hours ... the Happy Camp Ranger District of the Klamath National ... August 11, 2014. All but three of those fires ... list of contained fires and their size at containment: ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
... a heart attack. But the damage to heart muscle is ... the most common cause of death in developed countries. ... body can,t do: mending broken hearts. Engineers and physicians at ... the growth and integration of stem cell-derived cardiac muscle cells. ...
... RIVERSIDE, Calif. Anthony Norman , a ... policy changes regarding people,s vitamin D daily intake ... to reducing the frequency of many diseases, including ... hypertension, cardiovascular disease, obesity and muscle weakness. ...
... German . , Those who have to fight ... physicists from different scientific fields have decided to cooperate with ... through heat treatment by means of magnetic nanoparticles on a ... to improve the success of the therapy. Within the scope ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3Biochemist proposes worldwide policy change to step up daily vitamin D intake 2Biochemist proposes worldwide policy change to step up daily vitamin D intake 3How many nanoparticles heat the tumor? 2How many nanoparticles heat the tumor? 3
Rabbit Serum New Zealand or California Origin...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... be returned to customer conjugation of peptide to KLH protein ... 102 days/each , Pre-immune bleed x1 /each ... , Test bleed (app. 5 ml) x1 /each ...
...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: